CytoDyn Leadership Team To Attend ESMO Breast Canc

Quote:

---

CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany

---

The longest data out there for Trodelvy in mTNBC is 2 years.

Quote:

---

The 12 and 24 month survival rates (95% CI) for all patients were 40% (33–48%) and 23% (15–32%), respectively. In stratified analysis by SG line of therapy, rwOS was 13.9 (9.8–not estimable [NE]) months for patients receiving 2L SG and 8.4 (7.7–10.3) months for patients receiving 3L + SG (Fig. 3). The 12 and 24 month survival rates (95% CI) for patients receiving SG in 2L were 51% (37–64%) and 32%
https://pmc.ncbi.nlm.nih.gov/articles/PMC11452463/

---

Survival rate at 24 months. was 23% for all patients. You can see the importance of earlier treatment by looking at the real world overall survival in months and second line survival rates. 61% of patients in this trial were second line and third line. Real world overall survival in months dropped 40% for patients who were later than second line treatment. The overall survival rates in second line patients were 9% better than with all patients. Real world progression free survival (the cancer didn't get worse) at 24 months was only 3.8%.

Leronlimab was hampered by sub-optimal dosing in some patients and fourth line treatment or later in those from the trial itself. Even with that at 4 years we have an 18% overall survival and 14% with no evidence of cancer. If Trodelvy had managed to have surviving patients with no cancer at 2 years that would have certainly been reported in their trial results.